Hormones set the tempo for a woman’s life. They influence how steadily cycles run in the teens and twenties, how well ovulation supports fertility in the thirties, and how smoothly the perimenopause to postmenopause transition unfolds. When they are off, the body tells you. Sometimes with irregular periods or acne, other times with a string of negative pregnancy tests, or years later with hot flashes, brain fog, and sleep that fractures at 2 a.m. The right hormone therapy at the right time can be transformative. The wrong therapy, or therapy for the wrong reason, can lead to frustration, side effects, and avoidable risk.
What follows is a clinician’s view from years of working in hormone clinics and primary care, and collaborating with endocrinologists and fertility specialists. I will use the language patients use, including hormone replacement therapy, bioidentical hormones, and hormone optimization, while keeping the discussion grounded in what we know from good data and day to day practice.
What “normal” looks like across life stages
Ovarian hormones are not static. Estradiol and progesterone vary by day of cycle and by decade. A normal midluteal progesterone at 25 may be 12 to 20 ng/mL after a robust ovulation. The same woman at 37 may ovulate less predictably, with midluteal levels dipping under 10 ng/mL some cycles. By the mid forties, perimenopause stretches and compresses cycles, anovulatory months appear, and both estrogen and progesterone fluctuate widely. After the final menstrual period, estradiol falls into the postmenopausal range, often under 20 pg/mL, and progesterone becomes negligible.
Those shifts are not a defect. The question is how to support health, comfort, and goals at each stage using nutrition, sleep, stress management, and when appropriate, targeted hormone treatment.
Optimizing cycles in the reproductive years
Irregular or symptomatic cycles have many causes. I ask three questions before reaching for hormone therapy.
First, is ovulation happening consistently. A single luteal progesterone drawn about 7 days before the next period, not automatically on day 21, answers this. Levels over roughly 10 ng/mL indicate ovulation. If cycles vary from 24 to 35 days, time the test by counting back from the expected next period.
Second, are thyroid and prolactin normal. Subclinical hypothyroidism and mild hyperprolactinemia each can lengthen cycles and impair luteal function. Correct the root cause and cycles often normalize.
Third, does the phenotype suggest polycystic ovary syndrome. PCOS is common and varied. Some women have irregular cycles and high androgens, others have steady bleeding but metabolic features. Lifestyle, metformin, and targeted ovulation support often beat blanket hormone suppression for women who want to conceive. For those who do not, combined hormonal contraception can regulate bleeding and improve acne and hirsutism.
Hormone balancing in this stage is less about blanket hormone replacement and more about rhythm. Cyclic oral micronized progesterone, 200 mg nightly for 10 to 14 days each month, can stabilize the endometrium, improve sleep in the luteal phase, and reduce premenstrual mastalgia in women with long cycles or suspected luteal phase insufficiency. It is not a fertility cure on its own, but in selected patients who ovulate late and have short luteal phases, it can be part of a plan.
Combined oral contraceptives are an effective hormone treatment when contraception is also desired. They flatten peaks and valleys, reduce menstrual migraine frequency in some, help iron stores by lightening bleeding, and give ovarian cysts time to resolve. They do not optimize endogenous hormone production. That distinction matters when a patient asks for “natural hormone therapy.” If the goal is symptom relief and pregnancy avoidance, pills, patches, or rings can be a clean solution. If the goal is future fertility, I am more cautious with suppressive regimens and lean on cycle tracking, nutrition, and correcting metabolic drivers.
Fertility support without overpromising
True hormone deficiency in the reproductive years is rare outside hypothalamic amenorrhea, significant pituitary disease, or overt ovarian insufficiency. The more common pattern is mis-timed ovulation, inadequate folliculogenesis, or hostile endometrium, often aggravated by stress, underfueling, or insulin resistance. That is where a skilled hormone specialist earns their keep.
For anovulatory PCOS, ovulation induction with letrozole has better live birth rates and lower multiple gestation risk than clomiphene in many studies. A short course, properly monitored, often does more than months of supplements marketed as “hormone rebalancing.” In lean women with hypothalamic amenorrhea from overtraining or caloric deficit, the right prescription is food and rest. Adding estrogen and progesterone without restoring energy balance may induce withdrawal bleeds, but it rarely fixes anovulation.
Midluteal progesterone support deserves a nuance. In assisted reproduction, luteal support can improve outcomes. In natural cycles, routine progesterone after ovulation does not consistently improve live birth rates unless there is recurrent pregnancy loss with specific timing of deficiency. I do use it in women with classic short luteal phases and recurrent early bleeding, with clear counseling on the evidence.
Thyroid deserves an extra line. Treat hypothyroidism with levothyroxine in women trying to conceive, aiming for a TSH near or under 2.5 mIU/L. Subclinical disease with positive TPO antibodies may merit treatment depending on history. Avoid desiccated thyroid and T3 heavy regimens during preconception and pregnancy because of variable potency and risk of fetal exposure.
The perimenopause maze
Perimenopause is a decade long for some, a few years for others. Cycles become closer together, then spread out. Hot flashes arrive in waves, sleep fragments, and mood lability creeps in. Ironically, estrogen can be high on a given day, yet the overall pattern is unstable. Progesterone falls first because anovulation becomes more frequent. This is why luteal symptoms, migraines, and midcycle bleeding can worsen well before the last period.
When symptoms are mild, start with foundation work. Consistent morning light. Resistance training two or three days a week. Alcohol under seven drinks weekly, ideally under four, since alcohol amplifies hot flashes and sleep disruption. Magnesium glycinate at night can ease sleep onset and muscle tension. Cognitive behavioral therapy for insomnia helps even lifelong poor sleepers.
When symptoms impair life, perimenopause hormone therapy is reasonable. Many women do well with transdermal estradiol in low dose, combined with cyclic or continuous progesterone if they have a uterus. Others prefer combined hormonal contraception to suppress erratic ovulation and give predictable bleeding. Both strategies have trade offs. The combined pill offers contraception and steady bleeding control, but it uses ethinyl estradiol rather than estradiol and may raise clot risk slightly more than transdermal estradiol. Transdermal estradiol plus oral micronized progesterone can feel more physiologic and carries a lower venous thromboembolism risk than oral estrogen, but it does not provide contraception. Cycle history and risk profile guide the choice.
Menopause and HRT, done thoughtfully
Menopause marks 12 months without a period. At this point, estrogen is low and stable. Hormone replacement therapy is the most effective treatment for hot flashes and night sweats, and it often improves sleep, joint aches, vaginal dryness, and sexual comfort. It also preserves bone mineral density. The cardiovascular story is timing dependent. Starting HRT near menopause, typically before age 60 or within 10 years of the final period, carries a more favorable risk profile than starting late.
A practical way to begin is with transdermal estradiol at a low to moderate dose, titrated to symptom control, plus endometrial protection if the uterus is present. Oral micronized progesterone 100 mg nightly works well for many. A levonorgestrel intrauterine device can protect the endometrium and provide contraception for late perimenopause into early postmenopause. For women with surgical menopause or early primary ovarian insufficiency, HRT is health sustaining, not just symptom care. In these cases I generally continue systemic estrogen at least until the average age of natural menopause, unless contraindications emerge.
Vaginal estrogen deserves its own mention. Low dose local estrogen or prasterone can repair the vaginal epithelium, restore lubrication, and reduce urinary urgency and recurrent urinary tract infections. Blood levels remain in the postmenopausal range. Even in women who cannot take systemic estrogen, vaginal estrogen is often acceptable after a shared decision discussion with their oncology or primary team.
Who should not use systemic estrogen
- A history of estrogen dependent cancer without oncologist approval Unexplained vaginal bleeding, until evaluated Active or recent venous thromboembolism, stroke, or myocardial infarction Active liver disease with impaired function Known pregnancy
These are not the only cautions, but they are the hard stops that call for specialist input before proceeding.
Sorting routes and products without hype
Routes and preparations matter. Differences in first pass liver effects, peak and trough, and metabolite profiles translate into different risk and feel.
| Route or product | Typical use case | Pros | Cons or cautions | | --- | --- | --- | --- | | Transdermal estradiol patch, gel, or spray | Perimenopause and menopause systemic therapy | Steady levels, lower clot risk than oral, flexible dosing | Skin irritation for some, adherence matters | | Oral estradiol | Systemic therapy when patch is not acceptable | Convenient, predictable absorption | Higher clot and stroke risk than transdermal in at risk patients | | Oral conjugated estrogens | Legacy option | Works, covered by many plans | Non bioidentical mix, different risk profile | | Vaginal estradiol or DHEA (prasterone) | Genitourinary syndrome of menopause | Minimal systemic absorption, high local benefit | Does not treat hot flashes | | Oral micronized progesterone | Endometrial protection, sleep benefit | Sedating at night, bioidentical | Not sufficient alone for hot flashes | | Progestins, including levonorgestrel IUD | Endometrial protection, bleeding control | Strong protection, effective contraception | Mood changes in a subset, systemic side effects vary | | Testosterone for women, low dose transdermal | Hypoactive sexual desire disorder | Can improve desire and arousal | Acne, hair growth, voice change at high dose, pellets risky |
Bioidentical hormone therapy has two meanings in public conversation. One, FDA hormone therapy approved bioidentical hormones such as estradiol and micronized progesterone made to strict standards. Two, compounded bioidentical hormones made in compounding pharmacies to custom doses or mixtures. I use the first routinely. I am cautious with the second. Compounded bioidentical hormones fill gaps, for example for allergies to excipients or unusual doses, but they are not FDA approved, and potency can vary from batch to batch. Marketing that positions compounded pellets or troches as safer or more natural than regulated products is not evidence based.
Pellet hormone therapy gets extra scrutiny. Pellets can deliver estradiol or testosterone for months, but they bypass the ability to titrate dose. I have seen supraphysiologic testosterone levels for months after a single pellet in women, with acne, hair growth, and voice changes that did not fully reverse. For this reason I avoid pellet hormone implants in most women and prefer patches or gels that we can adjust or stop.
Hormone injections do have a role in specific contexts, such as estradiol valerate for those with severe malabsorption or transgender care, but for cisgender women managing perimenopause or menopause, injections are not first line.
Testosterone, DHEA, and the allure of “optimization”
Testosterone therapy in women has one evidence supported indication, hypoactive sexual desire disorder. When desire is persistently low, distressing, and not fully explained by relationship issues, depression, or medications, a low dose transdermal testosterone can help. The goal is to restore total testosterone to the physiologic female range for age, not to chase a number. I monitor side effects closely and keep an eye on hormone replacement New Providence hematocrit and lipids. Oral testosterone is not recommended due to unfavorable lipid effects. Pellets often overshoot. Most women who benefit do so on a small, measured transdermal dose.
DHEA appears in many wellness protocols as a catch all for fatigue or low libido. Systemic DHEA supplementation has inconsistent benefits and can drive acne or oily skin. Vaginal prasterone is useful for genitourinary symptoms. Systemic DHEA is best reserved for documented adrenal insufficiency or selected infertility settings under specialist care.
Growth hormone and IGF 1 therapies for anti aging are not advisable. They do not extend health span and they carry risks, including edema and insulin resistance. Cortisol therapy outside proven adrenal insufficiency is harmful. Real hormone optimization means matching therapy to deficiency or dysfunction, not forcing supernormal levels.
Safety, risk, and the WHI shadow
Every conversation about HRT lives in the shadow of the Women’s Health Initiative. Two decades on, we have a more nuanced picture. Combined oral conjugated equine estrogens plus medroxyprogesterone acetate in older postmenopausal women did increase breast cancer incidence modestly over time, and it increased clot and stroke risk. Estrogen alone in women without a uterus did not increase breast cancer risk and may have reduced it in some analyses. Age and time since menopause at initiation mattered. Transdermal estradiol and micronized progesterone likely carry a different, and in many cases lower, risk profile than the oral combination studied.
I translate this for patients as absolute risk over a realistic time frame. For an average risk 52 year old woman with severe vasomotor symptoms, five years of transdermal estradiol plus oral micronized progesterone likely confers a small absolute increase in breast cancer risk compared with not using HRT, similar in magnitude to the risk associated with drinking a glass of wine nightly. It will also reduce fractures and improve quality of life. For a 65 year old starting HRT for the first time, vascular risks weigh heavier, and nonhormonal options often come first. Family history, breast density, prior biopsies, and personal tolerance for risk all enter the decision.
Practical testing and monitoring without overtesting
Testing supports therapy, but more is not always better. Menopause is a clinical diagnosis after 45. Routine FSH testing is rarely needed to diagnose it. For perimenopause, estradiol and FSH hop around, so a single value seldom settles a debate. I prefer pattern recognition and symptom diaries.
When starting systemic HRT, I do not chase estradiol levels unless symptoms do not match dose, or side effects suggest overexposure. Progesterone levels are not helpful for women on oral micronized progesterone due to variable peaks. I check lipids and glucose periodically, especially if using oral estrogen or testosterone. Bone density testing follows standard age and risk based guidelines.
A simple follow up rhythm that works
- Reassess symptoms and blood pressure at 8 to 12 weeks after starting or changing HRT Review side effects, bleeding patterns, and dose adherence at each visit Check fasting lipids and A1c annually if cardiovascular risk is elevated or if oral estrogen or androgens are used Update breast screening per age and risk, and revisit the risk benefit balance every year
This cadence respects patient time, avoids lab churn, and still catches outliers.
Sleep, mood, and brain fog
Progesterone has GABAergic effects that can improve sleep onset. Many women tell me that 100 mg at night settled their mind in a way antihistamines never did. Estrogen stabilizes thermoregulation, which improves sleep maintenance by eliminating 2 a.m. heat spikes. For mood, HRT helps some but not all. It is not an antidepressant. SSRIs and SNRIs at low dose can shave hot flashes by a third to a half and help anxiety, which makes them a good bridge in women who cannot take estrogen. Cognitive complaints often reflect poor sleep, vasomotor disruption, and stress. Fix those first before leaning on supplements marketed as brain fog cures.
Weight, metabolism, and honest expectations
Weight gain around menopause is common, driven by aging, sleep changes, and a small metabolic shift. Estrogen therapy may reduce central fat gain and improve insulin sensitivity slightly, especially by the transdermal route, but it is not a weight loss drug. I set frank expectations. Dial in protein to around 1.2 to 1.6 g per kg body weight daily unless contraindicated. Maintain muscle with resistance training. Keep alcohol modest. If weight remains a major issue, consider dedicated obesity therapies. Do not expect HRT to replace GLP 1 receptor agonists or structured nutrition.
Working with the right clinician
A hormone doctor or hormone specialist is not a specific certification, but experience matters. You want someone who prescribes both estrogen and progesterone comfortably, prefers transdermal estradiol where appropriate, distinguishes between FDA approved bioidentical options and compounded bioidentical hormones, and will say no to pellet hormone therapy when the risks outweigh benefits. Endocrinologists, gynecologists, and primary care clinicians with a menopause focus can all fill this role. Functional medicine and integrative hormone therapy providers vary widely. Choose those who blend whole person care with evidence, not those who recommend growth hormone, cortisol, or supraphysiologic testosterone as anti aging hormone therapy.
If you are in a dedicated hormone clinic, ask how they monitor hormone levels, what products they use most, and how they handle side effects. Good answers mention symptom based titration, FDA approved estradiol and oral micronized progesterone, clear protocols for abnormal bleeding, and a plan to taper or pause HRT temporarily if needed.
Special situations and edge cases
Migraine with aura requires care. Transdermal estradiol has a better vascular risk profile than oral estrogen and is the only route I use in women with migraine with aura if we decide HRT is appropriate. Start low and watch how migraines behave.
Autoimmune disease can flare unpredictably around perimenopause. Estrogen can change immune tone. I coordinate with rheumatology and start with lower doses.
Smoking raises clot risk, more so with oral estrogen. I push hard for cessation before considering HRT, and I stick to transdermal routes.
Early menopause and primary ovarian insufficiency are different animals. Estrogen replacement is essential for bone, brain, and cardiovascular protection. Do not withhold HRT in these women unless there is a pressing contraindication.
Breast cancer survivors often fear any hormone. Local vaginal estrogen is usually reasonable for severe genitourinary symptoms after a risk discussion with the oncology team. Systemic HRT is generally avoided in estrogen receptor positive disease, but case by case exceptions exist.
Gender affirming hormone therapy follows different targets and regimens. This article centers on cisgender women’s care. Transgender hormone treatment, whether MTF or FTM, requires a separate, dedicated protocol with specific monitoring goals.
Pulling it all together
Hormone therapy is a tool, not a philosophy. Used well, it smooths perimenopause, restores comfort in menopause, stabilizes bleeding when cycles get chaotic, and supports fertility in clear, targeted ways. Used loosely, it veers into hormone optimization as a brand, with pellets, compounded blends, and promises that outpace evidence.
Start with the problem you are trying to solve. Name it clearly. Choose the simplest effective treatment. Prefer bioidentical estrogen and progesterone in regulated forms. Respect contraindications. Reassess at regular intervals. Keep lifestyle powerful and simple. And remember the goal is not perfect numbers on a panel. It is a life that runs more smoothly, with energy for the people and projects that matter, from the first irregular cycles to the last hot flash and long after.